Serum interleukin-38 levels correlated with insulin resistance, liver injury and lipids in non-alcoholic fatty liver disease

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Insulin resistance, liver injury and dyslipidemia are reported in non-alcoholic fat liver disease (NAFLD) patients. Interleukin (IL)-38 may take part in the pathophysiology of insulin resistance. Nevertheless, the function of IL-38 in NAFLD is unknown. Herein, we determined whether serum IL-38 level might be utilised as a biochemical marker for diagnosing NAFLD.

Methods

NAFLD patients and healthy participants ( n = 91 each) were enrolled. Circulating serum IL-38 levels were detected using enzyme-linked immunosorbent assay. Other metabolic and inflammatory indices related to NAFLD were also assessed.

Results

Patients with NAFLD had higher serum IL-38 levels than healthy individuals. Significantly higher serum IL-38 levels were found in patients with severe and moderate NAFLD than in patients with mild NAFLD. IL-38 showed a significant correlation with parameters of insulin resistance, inflammation, and liver enzyme in NAFLD cases. Anthropometric, insulin resistance, inflammatory parameters, lipids and frequency of NAFLD showed significant differences among the serum IL-38 level tertiles. Participants in the 2nd and 3rd tertiles of serum IL-38 levels had a greater risk of NAFLD than those in the 1st tertile. Furthermore, IL-38 ROC curve showed a high area under ROC with 0.861.

Conclusions

It is possible for serum IL-38 to be a biomarker for NAFLD.

Related collections

Most cited references 40

Record: found
Abstract: found
Article: not found

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease

Laurent Castéra, Mireen Friedrich-Rust, Rohit Loomba (2019)

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion individuals worldwide. In a subset of NAFLD patients, who have the progressive form of NAFLD termed nonalcoholic steatohepatitis (NASH), it can progress to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related morbidity and mortality. NASH is typically characterized by a specific pattern on liver histology, including steatosis, lobular inflammation, and ballooning with or without peri-sinusoidal fibrosis. Thus, key issues in NAFLD patients are the differentiation of NASH from simple steatosis and identification of advanced hepatic fibrosis. Until now, liver biopsy has been the gold standard for identifying these 2 critical end points, but has well-known limitations, including invasiveness; rare but potentially life-threatening complications; poor acceptability; sampling variability; and cost. Furthermore, due to the epidemic proportion of individuals with NAFLD worldwide, liver biopsy evaluation is impractical, and noninvasive assessment for the diagnosis of NASH and fibrosis is needed. Although much of the work remains to be done in establishing cost-effective strategies for screening for NASH, advanced fibrosis, and cirrhosis, in this review, we summarize the current state of the noninvasive assessment of liver disease in NAFLD, and we provide an expert synthesis of how these noninvasive tools could be utilized in clinical practice. Finally, we also list the key areas of research priorities in this area to move forward clinical practice.

0 comments Cited 568 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

Thomas G. Cotter, Mary Rinella (2020)

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the United States, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population, respectively. Considering the ongoing obesity epidemic beginning in childhood, the rise in diabetes, and other factors, the prevalence of NAFLD along with the proportion of those with advanced liver disease is projected to continue to increase. This will have an important impact on public health reflected in health care costs, including impact on the need for liver transplantation, for which nonalcoholic steatohepatitis is already close to becoming the most common indication. NAFLD patients with evidence of nonalcoholic steatohepatitis and advanced fibrosis are at markedly increased risk of adverse outcomes, including overall mortality, and liver-specific morbidity and mortality, respectively. Identification of this cohort of NAFLD patients is paramount, given the associated poorer outcomes, in order to target resources to those who need it most. Various noninvasive tools have been developed in this regard. This review provides an update on the epidemiology, clinical and prognostic features, and diagnostic approach to patients with NAFLD.

0 comments Cited 508 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Inflammation and lipid signaling in the etiology of insulin resistance.

Christopher K. Glass, Jerrold M. Olefsky (2012)

Inflammation and lipid signaling are intertwined modulators of homeostasis and immunity. In addition to the extensively studied eicosanoids and inositol phospholipids, emerging studies indicate that many other lipid species act to positively and negatively regulate inflammatory responses. Conversely, inflammatory signaling can significantly alter lipid metabolism in the liver, adipose tissue, skeletal muscle, and macrophage in the context of infection, diabetes, and atherosclerosis. Here, we review recent findings related to this interconnected network from the perspective of immunity and metabolic disease. Copyright © 2012 Elsevier Inc. All rights reserved.

0 comments Cited 173 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Guohui Xue: xueguohui0816@126.com

Journal

Journal ID (nlm-ta): Lipids Health Dis

Journal ID (iso-abbrev): Lipids Health Dis

Title: Lipids in Health and Disease

Publisher: BioMed Central (London )

ISSN (Electronic): 1476-511X

Publication date (Electronic): 10 August 2022

Publication date PMC-release: 10 August 2022

Publication date Collection: 2022

Volume: 21

Electronic Location Identifier: 70

Affiliations

[1 ]GRID grid.440811.8, ISNI 0000 0000 9030 3662, Department of Biochemistry and Molecular Biology, School of Medicine, , Jiujiang University, ; 17# Lufeng Road, Jiujiang, 332000 Jiangxi Province China

[2 ]Department of Clinical Laboratory, Jiujiang NO.1 People’s Hospital, 48# The South of Taling Road, Jiujiang, 332000 Jiangxi Province China

[3 ]Department of Endocrinology, Jiujiang NO.1 People’s Hospital, 48# The South of Taling Road, Jiujiang, 332000 Jiangxi Province China

[4 ]GRID grid.440811.8, ISNI 0000 0000 9030 3662, Department of pharmacology, School of Medicine, , Jiujiang University, ; 17# Lufeng Road, Jiujiang, 332000 Jiangxi Province China

Article

Publisher ID: 1676

DOI: 10.1186/s12944-022-01676-0

PMC ID: 9364532

PubMed ID: 35948957

SO-VID: a126c9be-dbb9-43c5-ab41-1cb6cdbd7a74

License:

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 15 May 2022

Date accepted : 18 July 2022

Custom metadata

ScienceOpen disciplines: Biochemistry

Keywords: non-alcoholic fatty liver disease,il-38,biomarker,insulin resistance,inflammation

Data availability:

ScienceOpen disciplines: Biochemistry

Keywords: non-alcoholic fatty liver disease, il-38, biomarker, insulin resistance, inflammation

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Cited by 2

See all cited by

Most referenced authors 496

See all reference authors

Serum interleukin-38 levels correlated with insulin resistance, liver injury and lipids in non-alcoholic fatty liver disease

Read this article at

Abstract

Background

Methods

Results

Conclusions

Related collections

GLUT4 biology

Most cited references 40

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

Inflammation and lipid signaling in the etiology of insulin resistance.

Author and article information

Contributors

Journal

Affiliations

Article

History

Categories

Custom metadata

Comments

Comment on this article

Similar content 107

Cited by 2

Most referenced authors 496